Developing advanced vaccines for melanoma using nanotechnology
Innovative Research for Cancer Nanotechnology (IRCN) for Enhancing Melanoma-specific Immune Responses by the Rational Design of Spherical Nucleic Acids
This study is testing a new type of vaccine made from tiny particles that could help your immune system better recognize and fight advanced melanoma, aiming to make immunotherapy more effective for people with this skin cancer.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Northwestern University NIH-funded |
| Lab location | 1 site (Chicago, UNITED STATES) |
| Project ID | NIH-11051247 on NIH RePORTER |
What this research studies
This research focuses on creating innovative vaccines for advanced melanoma by utilizing spherical nucleic acid (SNA) nanostructures. These vaccines are designed to enhance the immune response against melanoma cells, which often evade detection due to their high mutational burden. By controlling the presentation of multiple melanoma-associated targets to immune cells, the study aims to improve the effectiveness of immunotherapy. The approach involves synthesizing SNAs that combine both immunostimulatory components and tumor-associated peptides to boost antitumor responses.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with advanced melanoma who are seeking innovative treatment options.
Not a fit: Patients with early-stage melanoma or those who do not have a confirmed diagnosis of melanoma may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective vaccines that significantly improve immune responses against melanoma, potentially enhancing patient outcomes.
How similar studies have performed: Previous research has shown promising results with similar nanotechnology approaches in cancer immunotherapy, indicating potential for success in this novel application.
Where this research is happening
Chicago, UNITED STATES
- Northwestern University — Chicago, United States (Active)
Researchers
- Principal investigator: Mirkin, Chad a. — Northwestern University
- Study coordinator: Mirkin, Chad a.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.